Interferon treatment for corneolimbal squamous dysplasia

American Journal of Ophthalmology

Volumn 125, Issue 1, 1998, Pages 118-119

  Hu, Fung Rong ^a   Wu, Ming Jer ^b   Kuo, Sow Hsong ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

AGED; ARTICLE; CASE REPORT; CORNEA TUMOR; CORNEOLIMBAL SQUAMOUS DYSPLASIA; DYSPLASIA; HUMAN; HUMAN CELL; IMPRESSION CYTOLOGY; MALE; OPHTHALMOSCOPY; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; SUBCONJUNCTIVAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

EID: 0031984996     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)80252-9     Document Type: Article

References (5)

1. 1. Baron S, Tyring SK, Fleischmann WR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266:1375-1383.
2. 2. Maskin SL. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol 1994;112:1145-1146.
3. 3. Waring GO III, Roth AM, Ekins MB. Clinical and pathological description of 17 cases of corneal intraepithelial neoplasia. Am J Ophthalmol 1984;97:547-559.
4. 4. McDonnell JM, Mayr AJ, Martin WJ. DNA of human papillomavirus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea. N Engl J Med 1989;320: 1442-1446.
5. 5. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-245.